BIG
ABCL icon

Brooklyn Investment Group’s AbCellera Biologics ABCL Stock Holding History

Brooklyn Investment Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-177
Closed -$608 – 666
2025
Q2 		$608 Buy
+177
New +$441 ﹤0.01% 3050
2025
Q1 		– Sell
-634
Closed -$1.86K – 2768
2024
Q4 		$1.86K Buy
+634
New +$1.77K ﹤0.01% 1481

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Brooklyn Investment Group's ABCL Position: Q3 2025 in Review

Brooklyn Investment Group sold out of AbCellera Biologics (ABCL) in Q3 2025, closing a stake of 177 shares — an estimated $608 sold.

Brooklyn Investment Group first reported a position in ABCL in Q4 2024 and held it in 2 quarters. The position peaked at $1.86K in Q4 2024. 141 funds tracked by Wall St. Rank hold ABCL as of Q3 2025.

  • Brooklyn Investment Group reported no remaining AbCellera Biologics position as of Q3 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 177 AbCellera Biologics shares in Q3 2025, an estimated $608.
  • Brooklyn Investment Group first reported a position in AbCellera Biologics in Q4 2024 and held it in 2 quarters.
  • Brooklyn Investment Group's AbCellera Biologics position peaked at $1.86K in Q4 2024.
  • 141 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2025.

Based on Brooklyn Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.